RespireRx Transferes Its Pharmaceutical Cannabinoid Program To ResolutionRx
RespireRx Pharmaceuticals Inc. (OTCPK:RSPI), focused on the discovery and development of treatments to combat diseases caused by disruption of neuronal signaling, and ResolutionRx Ltd, an unlisted public Australian company, and a subsidiary of RespireRx on August 3, 2023, entered into a series of bilateral agreements intended to transfer the Re
